Clinical Trial Update: A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic studies evaluated how GSK2118436 (Dabrafenib) interacts with warfarin and how ketoconazole and gemfibrozil affect GSK2118436, including …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf-mutant Solid Tumors
• Cancer

Drugs mentioned

• GSK2118436 (dabrafenib)
• Gemfibrozil (Gemfibrozil)
• Ketoconazole (Ketoconazole)
• Warfarin (warfarin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED